No one wants to take away from India’s flair and prowess in the vaccines segment, but there should be no place for doubt when it comes to rigor in scientific and regulatory processes. Experts have raised questions around the restricted emergency use clearance of two COVID-19 vaccines in India.

UK biotech firm Emergex has signed a deal with Brazil’s Biocruz for the development of a T-cell based vaccine, and the Philippines regulator has issued a warning after reports that members of the country’s presidential guard received an unauthorized vaccine produced by China’s Sinopharm.

State-owned China National Biotec Group becomes the first to get the greenlight for its inactivated virus-based vaccine to prevent COVID-19.

Conditional approval guidelines were issued just days before regulators cleared a vaccine developed by state-owned China National Biotec Group.